Loading
Stomach cancer now has three add-on biomarkers (HER2, PD-L1, Claudin 18.2) that often overlap. Test whether combining two add-ons beats picking one.
Gastric cancer now has three first-line add-on biomarkers, HER2, PD-L1 and Claudin 18.2, which sometimes overlap. This idea asks whether tumours that are both CLDN18.2-positive and PD-L1 CPS 5 or higher do better with chemotherapy plus zolbetuximab plus PD-1 blockade than with chemotherapy plus a PD-1 inhibitor alone. The rationale is that the two add-ons act through non-overlapping mechanisms, antibody-dependent cellular cytotoxicity versus T-cell release, and zolbetuximab-induced cell death may increase antigen presentation. Zolbetuximab with nivolumab is under study in ILUSTRO, HERIZON-GEA-01 combined zanidatamab with tislelizumab, and the proposed test is a randomised phase 3 in double-positive patients, at an early clinical stage.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2-positive gastric cancer, Claudin 18.2.
Shares Zolbetuximab, Zanidatamab, Claudin 18.2, HER2.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Nivolumab.
Shares Zolbetuximab, Claudin 18.2-positive gastric cancer, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
Shares CheckMate 649, HER2, Nivolumab, PD-1.
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, HER2.
Shares HERIZON-GEA-01, Zanidatamab, HER2, Gastric & gastro-oesophageal junction cancer.